Diphenylpyraline

Diphenylpyraline

Clinical data
Other names	4-(diphenylmethoxy)-1-methyl-piperidine
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, Topical
ATC code	R06AA07 ( WHO )
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life	24–40 hours [1]
Identifiers
IUPAC name 4-benzhydryloxy-1-methyl-piperidine
CAS Number	147-20-6  Y
PubChem CID	3103
IUPHAR/BPS	7165
DrugBank	DB01146  Y
ChemSpider	2992  Y
UNII	33361OE3AV
KEGG	D07862  Y
ChEBI	CHEBI:59788  Y
ChEMBL	ChEMBL1492  Y
CompTox Dashboard (EPA)	DTXSID3022952
ECHA InfoCard	100.005.170
Chemical and physical data
Formula	C19H23NO
Molar mass	281.399 g·mol−1
3D model (JSmol)	Interactive image
SMILES O(C(c1ccccc1)c2ccccc2)C3CCN(C)CC3
InChI InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 Y Key:OWQUZNMMYNAXSL-UHFFFAOYSA-N Y
(verify)

Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenyl piperidine class. ^{[2] [3] [4]} It is marketed in Europe for the treatment of allergies. ^{[2] [3] [5]} DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents. ^[6] It has been shown to be useful in the treatment of Parkinsonism. ^[7]

Synthesis

Diphenylpyraline synthesis via coupling of benzhydrylbromide [776-74-9] (1) with 4-hydroxy-1-methylpiperidine [106-52-5] (2) by refluxing in xylene for 24 hours. ^{[8] [9]}

See also

• Hepzidine is self-same but is instead based on a dibenzosuberone nucleus.

References

1. Graham G, Bolt AG (June 1974). "Half-life of diphenylpyraline in man". Journal of Pharmacokinetics and Biopharmaceutics. 2 (3): 191–5. doi:10.1007/BF01059761. PMID   4156058. S2CID   38955052.
2. Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN   3-88763-075-0.
3. Puhakka H, Rantanen T, Virolainen E (1977). "Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis". J Int Med Res. 5 (1): 37–41. doi:10.1177/030006057700500106. PMID   14039. S2CID   19330175.
4. Kubo N, Shirakawa O, Kuno T, Tanaka C (March 1987). "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay". Japanese Journal of Pharmacology. 43 (3): 277–82. doi: 10.1254/jjp.43.277 . PMID   2884340.
5. Hruby VJ, Vardanyan R, Vardanyan R (2006). "Antihistamine Drugs". Synthesis of Essential Drugs. Amsterdam: Elsevier. ISBN   0-444-52166-6.
6. Lapa G, Mathews T, Harp J, Budygin E, Jones S (2005). "Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties". Eur J Pharmacol. 506 (3): 237–40. doi:10.1016/j.ejphar.2004.11.017. PMID   15627433.
7. Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001). "Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients". J Neurol Sci. 182 (2): 95–7. doi:10.1016/S0022-510X(00)00441-X. PMID   11137513. S2CID   35946097.
8. US 2479843,Knox LH, Kapp R,"1-Alkylpiperidyl-4-benzhydryl ethers, acid salts thereof and their preparation",issued 23 August 1949, assigned to Nopco Chemical Company. 
9. DE 934890, Schuler WA,"Verfahren zur Herstellung von basischen Benzhydryläthern [Process for the production of basic benzhydrylethers]",issued 10 November 1955, assigned to Chemische Fabrik Promonta LLC.